MedTrace Logo

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 327

Last updated 2013-04-09

Study results available
· View outcomes & findings →

Summary

A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

CP-690,550

Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks

DRUG

CP-690,550

Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks

DRUG

CP-690,550

Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks

DRUG

CP-690,550

Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks

DRUG

Cyclosporine

Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks

DRUG

CP-690,550 Vehicle

Ophthalmic topical solution, dosed at least once/day, 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00784719 on ClinicalTrials.gov